|
SUN-S 461 is an anti-inflammatory molecule for use in the treatment of asthma / allergic rhinitis and COPD.
Essentially a glucocorticoid receptor agonist, this molecule belongs to the category called soft corticosteroids. In soft corticosteroids, an affinity for the metabolic pathway for deactivation is built within the molecule itself. Clinically, this translates into significantly lower systemic side effects.
Soft corticosteroids are designed based on a retrometabolic approach. In this design, an active as well as an inactivation site are constructed within the structure of potent glucocortcoid molecules. These drugs produce the desired pharmacological effect at the site of action, but are inactivated through rapid metabolism once absorbed from the site into the system. Thus there is lesser likelihood of producing steroid associated side effects, unlike in classical corticosteroids.
In preclinical studies, SUN-S461 has demonstrated suppression of inflammatory response (antiinflamatory activity) which was comparable to currently marketed steroids with a better side effect profile.
The molecule will now enter futher stages of clinical testing.
| 
Active Projects in Drug Discovery in focused therapy areas with known biology.
